Curis, Inc., a biotechnology company focused on developing emavusertib, announced its business update and financial results for the fourth quarter ended December 31, 2025, according to a March 19 statement.
The update is significant as it outlines Curis’s recent financial performance, operational highlights, and future funding plans. The company reported a net income of $19.4 million or $1.23 per share for the fourth quarter of 2025, compared to a net loss of $9.6 million or $1.25 per share in the same period in 2024. For the full year 2025, Curis posted a net loss of $7.6 million, an improvement from the previous year’s net loss of $43.4 million.
Revenues for the year were $9.4 million, down from $10.9 million in 2024, primarily consisting of royalty revenues related to Genentech and Roche’s sales of Erivedge. In November 2025, Curis sold its interest in Curis Royalty LLC—including Erivedge intellectual property—to TPC Investments Royalty LLC for upfront consideration of $2.5 million and release from future royalty liabilities.
Research and development expenses decreased to $28.3 million in 2025 from $38.6 million in 2024 due to lower employee-related and clinical costs. General and administrative expenses also declined to $14 million from $16.8 million over the same period.
As of December 31, 2025, Curis held cash and cash equivalents totaling $5.1 million with approximately 12.9 million shares outstanding. The company closed a private placement financing in January 2026 with gross proceeds up to $80.8 million; initial proceeds were about $20.2 million with additional funds possible through warrant exercises tied to milestones in its TakeAim CLL study later this year.
Curis believes that its current cash position plus expected proceeds should fund operations into the second half of 2027 but notes that substantial additional capital will be required for continued development and regulatory approval efforts for emavusertib.
A conference call was scheduled for March 19 at 4:30 p.m ET to discuss these updates further.
PR Newswire operates in more than 170 countries and supports distribution in over 40 languages according to the official website. The service aims to deliver global reach through its network of newsrooms and influencers as detailed on its official website. PR Newswire features expert editors providing round-the-clock support and SEO guidance according to its official website. It collaborates with over half a million media outlets and influencers worldwide according to the official website while offering services such as press release distribution, AI-enhanced content tools, and social sharing features as outlined on its official site.
